EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Comparability of GFAP and UCH-L1 Measurements Using Handheld and Core Laboratory TBI Plasma Tests and Their Diagnostic Performance for Traumatic Intracranial Lesions

Nathan B Roberts, Carmen Gherasim, Kexin Li, Tian Xie, Hayley Falk, Jayapalli Bapuraj, Debra Demski, Christopher M Fung, Nathan L Haas, Keith E Kocher, Katharine S Seagly, Richard P Medlin, Jacob Joseph, Matthew J Schipper, Raj Chandran, Jaime A Marino, Beth McQuiston, Swati Pradhan-Bhatt, Frederick K Korley

The Journal of Applied Laboratory Medicine · 2026-11-04 · 11 (6) · 1364-1377

DOI: 10.1093/jalm/jfag093 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background Glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) are cleared by the U.S. Food and Drug Administration (FDA) to aid computed tomography (CT) decision-making in patients with traumatic brain injury (TBI). Two commercial assays, i-STAT TBI Plasma test and Alinity i TBI test, quantify these biomarkers using distinct detection technologies. Limited comparative data exist, creating uncertainty about cross-platform agreement and interchangeability of results in clinical and research applications. Methods GFAP and UCH-L1 concentrations were measured twice from 829 adults who underwent brain CT within 24 h of blunt trauma, first using the Abbott i-STAT TBI Plasma test and second using the Alinity i TBI test. Agreement was assessed using percent agreement (binary outcomes), Bland–Altman plots, Passing–Bablok regression, and Pearson correlation, with and without imputed values for out-of-range results. Diagnostic accuracy for traumatic intracranial lesions (tICLs) was calculated at assay-specific cutoffs. Results For GFAP + UCH-L1 in combination, the overall cross-platform agreement was 92.28%. GFAP and UCH-L1 showed strong cross-platform correlations with imputed (r = 0.916 and 0.916, respectively) and non-imputed data (r = 0.942 and 0.909, respectively). Both tests detected all clinically significant tICLs, with sensitivities of 100% (95% CI, 89%–100%) and negative predictive value (NPV) of 100% (95% CI, 98%–100%). Specificities were 29% (95% CI, 26%–32%) for i-STAT and 25% (95% CI, 22%–28%) for Alinity i. Conclusions GFAP and UCH-L1 showed strong cross-platform agreement, individually and in combination, with equivalent sensitivity for tICL, supporting clinical interchangeability of the binary positive/negative test results.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →